Leap Therapeutics Inc (LPTX)

$3.50+ 😃

$LPTX / $CYPH 💹

Hey bluebird50. Here's a little bit more info about LPTX / CYPH.

Leap Therapeutics Becomes Cypherpunk, Commits $50M to Zcash Treasury Strategy
Cypherpunk Technologies reveals a $50 million Zcash acquisition and leadership overhaul in its crypto shift

Nov 13, 2025

• Cypherpunk invested $50M to acquire 203,775.27 ZEC, signaling a long-term privacy asset strategy shift.
• The firm will trade under ticker CYPH from November 13 after its Leap Therapeutics rebrand.
• Winklevoss Capital led the $58.88M private placement that financed Cypherpunk’s Zcash treasury move.
• Zcash’s zk-SNARKs technology and fixed 21M supply underpin Cypherpunk’s privacy-focused blockchain vision.

Cypherpunk Technologies, formerly Leap Therapeutics, has entered the digital asset space with a decisive move. The Nasdaq-listed firm confirmed its rebranding and the launch of a $50 million Zcash treasury initiative.

The transition also includes a ticker change to CYPH effective November 13. The company’s pivot marks one of the most aggressive corporate shifts toward privacy-focused blockchain assets in 2025.

Cypherpunk Acquires Over 200K Zcash in Treasury Push
According to a company press release, Cypherpunk Technologies used proceeds from a recent $58.88 million private placement to purchase 203,775.27 ZEC at an average price of $245.37 per token. The acquisition underscores the firm’s long-term bet on Zcash, one of the most established privacy-preserving cryptocurrencies.

The financing round was led by Winklevoss Capital, the only institutional investor in the placement, which contributed the majority of funds raised.

The firm’s new strategy focuses on positioning Zcash as a core treasury asset alongside its operational rebrand. The company emphasized that the decision aligns with a broader mission to promote privacy-focused blockchain infrastructure.

As part of the leadership restructuring, Khing Oei has been named Chairman of the Board, while Will McEvoy assumes the role of Chief Investment Officer. Both appointments took effect on November 11.

According to the company, this leadership team will oversee treasury growth and digital asset management as part of its expanded corporate mission.

Trading under the CYPH ticker begins on November 13, allowing investors to engage with the stock under its new identity. The firm’s previous Chairman, Christopher Mirabelli, will remain on the board, ensuring continuity during the transition.
Privacy and Self-Sovereignty at the Core of Cypherpunk’s Vision

Cypherpunk’s new strategy is grounded in the belief that privacy represents both a social necessity and an economic opportunity. The company described privacy as the “silent precondition of freedom,” emphasizing its role in enabling speech, association, and personal autonomy in the digital age.

Zcash, launched in 2016 as a Bitcoin fork, employs advanced zero-knowledge proofs (zk-SNARKs) to allow transaction validation without disclosing amounts or participants. The protocol’s continuous evolution, including upgrades like Halo 2, enhances scalability and security without relying on trusted setups.

Zcash remains one of the few privacy coins maintaining consistent network development and decentralization metrics. Its capped supply of 21 million coins mirrors Bitcoin’s monetary model, but with embedded privacy utility.

Cypherpunk’s move positions it to benefit from this dual nature, monetary soundness with enhanced confidentiality.

The company framed Zcash as a form of “digital privacy in asset form,” viewing it as a counterbalance to Bitcoin’s transparency. As blockchain adoption expands across financial systems, Cypherpunk aims to lead corporate engagement with privacy technologies that protect user sovereignty in a data-driven world.

https://blockonomi.com/leap-therapeutics-becomes-cypherpunk-commits-50m-to-zcash-treasury-strategy/

$LPTX / $CYPH

It changes to CYPH this morning. 
The Company will begin trading on the Nasdaq Capital Market under the ticker symbol "CYPH" at the market open on November 13, 2025.

https://www.newswire.ca/news-releases/cypherpunk-technologies-formerly-leap-therapeutics-reports-third-quarter-2025-financial-results-809271602.html

Did the company changed its symbol?

How DDAmanda Found $LPTX Early: +369%. Best Early Alert Stock Finder

DDAmanda finds these before they run.



Z

Good thing or bad? 

$2.45+ 🚀

$LPTX 💹

👍🏽👍🏽👍🏽

Wow $1.84 now!

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

Nov 12, 2025

https://www.newswire.ca/news-releases/cypherpunk-technologies-formerly-leap-therapeutics-reports-third-quarter-2025-financial-results-809271602.html

$LPTX

LPTX.............................................................https://stockcharts.com/sc3/ui/?s=LPTX&p=W&b=5&g=0&id=p86431144783

new hod… 🤓 

setting uP a reversal doji… 🤓 

3 gap down pattern forming here 🤓 https://schrts.co/aZRADTDZ

Let's go !! Digital assets ! 

Something huge is coming, breakthrough!

"News on digital assets strategy " coming imminent, any time.

"Leap expects to release additional updates regarding its treasury activities in the near-term."

slaps coming in 🤓 

Let's eee! I want news on digital assets strategy 

readying to bounce for the .53 bust, then .60 .80 quickly 🤓 https://schrts.co/RdSFsuZY

Dude they lockedWrong time for their pre 14 filing 

Research this . We are next VivoPower $VVPR Announces XRP-Focused Digital Asset Treasury Strategy and US$121 Million Private Placement Priced at US$6.05 Per Share, Above Last Market Closing Price Under NASDAQ Rules

𝗥𝗘𝗔𝗗 https://t.co/Tf10EkwbUy pic.twitter.com/u0U7ND5KfR— VivoPower_PLC (@Vivo_Power) May 28, 2025

Yes we got to eventually get to over $1 and the news should takeUs there 

aDD…

nothing but down, meanwhile BYND rocket

welcome to the Matrix

LPTX going uP here...

....

https://investors.leaptx.com/news-releases/news-release-details/leap-therapeutics-presents-final-data-defiance-study-esmo-2025/

Ready to see tomorrows candle... Sometimes it takes a bit for news to get around 🤓 

LPTX, $0.55, Amazing news out: demonstrated statistically significant improvement on lung cancer:

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
PR Newswire

CAMBRIDGE, Mass., Oct. 20, 2025

Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population

Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm

Leap to continue supporting development of sirexatamab in DKK1-high CRC patients

CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. The final clinical results were presented on behalf of the DeFianCe study investigators by Zev Wainberg, MD, Professor of Medicine and Co-Director of the GI Oncology Program at UCLA in a Mini Oral session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.

Sunday news...“CAMBRIDGE, Mass., Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present the final clinical results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. The final results will be presented in a Mini Oral Session at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany.”

readying to bounce here 🤓 

.59 here, they are skipping my bids…

setting uP an inverted hammeR 🔨 

Just waiting ...🥳

.6050 Someone loading up today heavy at .60 net accumulation 1.8m shares ...ready to fly anytime market makers let the goose loose one more time..$2 target 

.60 Oct 19th news date.. The final results will be presented in a Mini Oral Session at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany.Mini Oral Session Details:Title: DeFianCe Trial: A randomized phase 2 trial of sirexatamab (DKN-01) plus bevacizumab and chemotherapy versus bevacizumab and chemotherapy as second-line therapy in advanced microsatellite stable (MSS) colorectal cancer (CRC)
Presenter: Zev A. Wainberg, M.D., Professor of Medicine and Co-Director of the GI Oncology Program at UCLA
Session Type: Mini Oral Session  
Session Category: GI Tumours, Lower Digestive
Date and Time: Sunday, October 19, 2025, 4:05 p.m. CEST..

aDDing... 🤓 

LPTX...75...🥳...Strong News...https://finviz.com/news/187902/leap-therapeutics-announces-closing-of-5888-million-private-placement-in-cash-led-by-winklevoss-capital-to-initiate-a-digital-asset-treasury-strategy

Volume Proceeds Price LPTX Going To Dollars

.75sss

.73sss

readying to keep cranking out hods… 🤓  

LPTX might submit an application for FDA soon. We'll see.

setting uP a Bullish Harami 🤓  

creepin’ uP 🤓  

It hit 3 last night? Winklevoss.involvment--sounds interesting

Torture hits $3.00 Plus Then Tanks Right Back Down. WTF

 Saw $1.60s but was busy with other stocks so have to wait again for $2+ 

It touched $3.5 this morning. The results for cancer must be very good. They know better.

Looking good half off .76 still looking at $2